Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Bellevue Group AG

Bellevue Group AG grew its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,103,136 shares of the medical research company’s stock after purchasing an additional 84,138 shares during the period. Edwards Lifesciences accounts for about 1.6% of Bellevue Group AG’s investment portfolio, making the stock its 18th largest position. Bellevue Group AG owned about 0.18% of Edwards Lifesciences worth $105,416,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth about $28,000. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences in the first quarter valued at approximately $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth approximately $34,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $34,000. Finally, Pingora Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $38,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the topic of several research reports. Citigroup increased their target price on Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. Royal Bank of Canada reduced their price objective on Edwards Lifesciences from $101.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday. TD Cowen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the company from $100.00 to $70.00 in a report on Thursday. Oppenheimer decreased their price objective on shares of Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Wells Fargo & Company cut their target price on shares of Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating on the stock in a research note on Thursday. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $82.10.

Edwards Lifesciences Stock Up 4.5 %

NYSE EW traded up $2.67 during trading hours on Friday, reaching $62.37. 14,111,391 shares of the company traded hands, compared to its average volume of 5,310,790. The company has a 50 day moving average of $87.98 and a two-hundred day moving average of $86.99. The stock has a market capitalization of $37.58 billion, a PE ratio of 26.88, a PEG ratio of 2.31 and a beta of 1.11. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period last year, the firm earned $0.66 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total value of $622,050.00. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,636,549.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Scott B. Ullem sold 7,250 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total transaction of $622,050.00. Following the completion of the transaction, the chief financial officer now owns 19,074 shares in the company, valued at approximately $1,636,549.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bernard J. Zovighian bought 580 shares of the company’s stock in a transaction on Monday, May 6th. The stock was bought at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the transaction, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 81,099 shares of company stock valued at $7,003,553. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.